• BriaCell scheduled six clinical data disclosures for 2026 ASCO Annual Meeting, including final randomized Phase 2 survival and quality-of-life results for Bria-IMT with an immune checkpoint inhibitor in advanced metastatic breast cancer.
• Results have not yet been presented; poster presentations are set for June 1, 2026, with abstracts due May 21, 2026.
• Company also plans to present ongoing Phase 3 Bria-ABC biomarker work aimed at identifying blood-based predictors of treatment response.
• Three additional publication-only abstracts will outline work on second-generation cell therapy BC1 and liquid-biopsy approaches intended to stratify risk or predict outcomes in metastatic breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270730PRIMZONEFULLFEED9696798) on April 27, 2026, and is solely responsible for the information contained therein.